Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03035864
Recruitment Status : Completed
First Posted : January 30, 2017
Results First Posted : July 22, 2019
Last Update Posted : July 22, 2019
Sponsor:
Information provided by (Responsible Party):
Dompé Farmaceutici S.p.A

Brief Summary:

The primary objective of this exploratory study is to assess preliminary efficacy and safety of rhNGF when administered as eye drops to patients after cataract and refractive surgery.

The main criteria for evaluation were:

  • Change from baseline in SANDE scores for severity and frequency assessed at 8 weeks of treatment (primary efficacy endpoint)
  • Changes in Cornea vital staining with fluorescein (National Eye Institute [NEI] scales) assessed at 8 weeks of treatment (co-primary efficacy endpoint)
  • Changes in conjunctiva vital staining with fluorescein (NEI scales) (secondary efficacy endpoint);
  • Changes in Tear Film Break-Up Time (TFBUT)(secondary efficacy endpoint);
  • Changes in Cochet-Bonnet corneal aesthesiometry (secondary efficacy endpoint);
  • Changes in Nerve count and morphology at scanning laser in vivo corneal confocal microscopy (only patients who had Laser-Assisted In situ Keratomileusis [LASIK] surgery) (secondary efficacy endpoint);
  • Changes in SANDE scores (face values) for severity and frequency (secondary efficacy endpoint);
  • Incidence and frequency of treatment-emergent adverse events (TEAEs), assessed throughout the study (safety endpoint).

Condition or disease Intervention/treatment Phase
Ocular Discomfort Drug: rhNGF Other: Vehicle Phase 2

Detailed Description:

The proposed phase II study is a single-centre, randomized, double masked, parallel arm, vehicle-controlled trial, designed to evaluate the preliminary efficacy and safety of rhNGF eye drops at 20 µg/ml concentration administered six times daily for 8 weeks in patients who underwent cataract and corneal refractive surgery, both known to damage the corneal sensory nerve plexus.

After confirmation of inclusion and exclusion criteria all eligible patients will be randomized at 2:1 ratio to rhNGF or vehicle control treatment with 8 weeks of study treatments administration with 4 weeks Follow-up.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: For the whole duration of the trial, treatment was unknown to the patient, the Investigator and the site staff.
Primary Purpose: Treatment
Official Title: A 8 Weeks, Phase II, Single-centre, Randomized, Double-masked, Vehicle-controlled, Parallel Group Study With 4 Weeks Follow-up to Evaluate Efficacy & Safety of rhNGF Eye Drops vs Vehicle in Patients After Cataract and Refractive Surgery
Actual Study Start Date : January 12, 2017
Actual Primary Completion Date : September 4, 2017
Actual Study Completion Date : September 4, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: rhNGF 20 µg/ml
Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
Drug: rhNGF
Eye Drop 20 μg/mL
Other Name: NGF

Placebo Comparator: Vehicle
Vehicle eye drops six times daily
Other: Vehicle
Vehicle Eye Drop




Primary Outcome Measures :
  1. Change From Baseline in SANDE Scores for Frequency and Severity Assessed at 8 Weeks of Treatment. [ Time Frame: Baseline and Week 8 ]

    The Symptom Assessment in Dry Eye (SANDE) questionnaire is a short questionnaire to evaluate both dry eye intensity and frequency by using a 100 mm visual analogue scale (VAS). The patient symptoms of ocular dryness and/or irritation were quantified on the scale based on two questions that assessed both the severity and frequency of symptoms.

    The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.


  2. Changes in Cornea Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) [ Time Frame: Baseline and Week 8 ]
    Corneal Staining was derived as the sum of scores of the five corneal sectors (central, superior, inferior, nasal, and temporal) each of which was scored on a scale of 0-3, with a minimum score of 0 and a maximal score of 15 (sum > 3 out of 15 is abnormal).


Secondary Outcome Measures :
  1. Changes in Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales) [ Time Frame: From baseline to weeks 4, 8 and 12 ]

    Conjunctival Staining was derived as the sum of scores of the conjunctival area (nasal-superior paralimbal, nasal-inferior paralimbal, nasal-peripheral, temporal-superior paralimbal, temporal-inferior paralimbal, temporal-peripheral) with a grading scale of 0-3 and with a minimum score of 0 and a maximal score of 18 (18 indicates the most abnormal score). Grades increase with the number and density of dots.

    Data for the main eye are reported.


  2. Changes in Tear Film Break-Up Time (TFBUT) [ Time Frame: From baseline to weeks 4, 8 and 12 ]

    The TFBUT measurement was performed after instillation of 5 microliters of 2% sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film.

    Data for the main eye are reported.


  3. Changes in Cochet-Bonnet Corneal Aesthesiometry [ Time Frame: From baseline to week 8 ]

    Corneal sensation was measured in both eyes in each of the four quadrants of the cornea using the Cochet Bonnet aesthesiometer before the instillation of any dilating or anesthetic eye drops. The handheld esthesiometer (Cochet-Bonnet) is a device that contains a thin, retractable, nylon monofilament that extends up to 6 cm in length. Variable pressure can be applied by the device by adjusting the length. The monofilament ranges from 60 mm to 5 mm and as the length is decreased the pressure increases from 11 mm/gm to 200 mm/gm.

    Data for the main eye are reported.


  4. Changes in SANDE Scores (Face Values) for Frequency and Severity [ Time Frame: From baseline to weeks 4, 8 and 12 ]

    The Symptom Assessment in Dry Eye (SANDE) questionnaire is a short questionnaire to evaluate both dry eye intensity and frequency by using a 100 mm visual analogue scale (VAS). The patient symptoms of ocular dryness and/or irritation were quantified on the scale based on two questions that assessed both the severity and frequency of symptoms.

    The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female ≥18 years old
  2. Patients who are characterized by the following clinical features:

    1. History of cataract or refractive corneal surgery in the study eye(s) in the previous 6 months;
    2. Mean Symptom Assessment in Dry Eye (SANDE) score for severity and frequency of at least 30 at baseline
  3. The same eye (study eye) must fulfill all the above criteria
  4. Best corrected distance visual acuity (BCDVA) score of ≥ 0.1 decimal units in both eyes at the time of study enrolment
  5. Female patients must have negative pregnancy urine test if at childbirth potential.
  6. Only patients who satisfy all requirements for informed consent may be included in the study. Written Informed Consent must be obtained before the initiation of any study-specific procedures.
  7. Patients must have the ability and willingness to comply with study procedures

Exclusion Criteria:

  1. Any ocular disease other than Dry Eye requiring treatment with topical medications in either eye at the time of study enrolment.
  2. Any active ocular infection or active inflammation in either eye unrelated to Dry Eye.
  3. Presence or history of any systemic or ocular disorder, condition or disease (with particular attention to malignancies and neuro-oncological diseases) that could possibly interfere with the conduct of the required study procedures or the interpretation of the study results.
  4. Use of therapeutic or Refractive Contact lenses in either eye at the time of study enrolment;
  5. History of ocular surgery in the study eye(s), excluding corneal refractive or cataract procedures, within 90 days of study enrolment.
  6. Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:

    1. are currently pregnant or,
    2. have a positive result at the urine pregnancy test (Baseline/Day 0) or,
    3. intend to become pregnant during the study treatment period or,
    4. are breast-feeding or,
    5. are not willing to use highly effective birth control measures, such as: hormonal contraceptives - oral, implanted, transdermal, or injected - and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or IUD (Intrauterine device) - during the entire course of and 30 days after the study treatment periods.
  7. Participation in another clinical study at the same time as the present and within 30 days of study enrolment;
  8. History of drug, medication or alcohol abuse or addiction.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03035864


Locations
Layout table for location information
Italy
Univ. G. D'Annunzio-Clinica Oftalmologica-Chieti
Chieti, Italy
Sponsors and Collaborators
Dompé Farmaceutici S.p.A
Investigators
Layout table for investigator information
Principal Investigator: Leonardo Mastropasqua, MD Univ. G. D'Annunzio- Clinica Oftalmologica Chieti
  Study Documents (Full-Text)

Documents provided by Dompé Farmaceutici S.p.A:
Study Protocol  [PDF] April 12, 2017
Statistical Analysis Plan  [PDF] July 11, 2017


Layout table for additonal information
Responsible Party: Dompé Farmaceutici S.p.A
ClinicalTrials.gov Identifier: NCT03035864     History of Changes
Other Study ID Numbers: NGF0116
First Posted: January 30, 2017    Key Record Dates
Results First Posted: July 22, 2019
Last Update Posted: July 22, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dompé Farmaceutici S.p.A:
Ocular discomfort after cataract and refractive surgery
cataract surgery
refractive surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Cataract
Capsule Opacification
Lens Diseases
Eye Diseases
Ophthalmic Solutions
Pharmaceutical Solutions